SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PROTEOMICS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject9/26/2000 6:52:25 AM
From: nigel bates  Read Replies (1) of 539
 
Sept. 26 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - news) announced today that it has discovered a novel drug target for the treatment of human infection by the hepatitis B virus (HBV). The target was discovered using Myriad's ProNet® proteomics technology to investigate the viral-human protein interactions.
The drug target is a protein that, Myriad believes, has not been explored previously for drug development, and represents a totally new approach to the problem of treating viral diseases. The HBV target followed the same therapeutic target discovery strategy that has been applied successfully by Myriad in the identification of drug targets in AIDS. It is also now being used to discover novel therapeutic intervention points in additional viral diseases such as Herpes Simplex virus and Hepatitis C.
``We are seeing strong progress throughout the drug discovery and early development stages of our pipeline,'' said Dr. Adrian Hobden, President of Myriad Pharmaceuticals, Inc. ``The viral diseases as a class represent an excellent opportunity for drug discovery and HBV is an intriguing and important target. There are few disease fields that offer more potential to reduce the burden of human suffering.''
The addition of this new HBV target raises Myriad Pharmaceuticals' total to 36 drug discovery programs. These targets are derived from the analysis of 225 proteins run through ProNet pathway discovery. High-throughput screening has been initiated on 17 of the targets. Drug targets in high-throughput screening are from the disease fields of cancer, inflammatory disease and viral infection....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News